345 related articles for article (PubMed ID: 17453821)
1. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
3. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
4. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
Gennatas C; Michalaki V; Carvounis E; Psychogios J; Poulakaki N; Katsiamis G; Voros D; Kouloulias V; Mouratidou D; Tsavaris N
Tumori; 2006; 92(1):13-7. PubMed ID: 16683378
[TBL] [Abstract][Full Text] [Related]
5. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
6. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Iwata H; Masuda N; Ohno S; Rai Y; Sato Y; Ohsumi S; Hashigaki S; Nishizawa Y; Hiraoka M; Morimoto T; Sasano H; Saeki T; Noguchi S
Breast Cancer Res Treat; 2013 Jun; 139(2):441-51. PubMed ID: 23715630
[TBL] [Abstract][Full Text] [Related]
8. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Campos SM; Guastalla JP; Subar M; Abreu P; Winer EP; Cameron DA
Clin Breast Cancer; 2009 Feb; 9(1):39-44. PubMed ID: 19299239
[TBL] [Abstract][Full Text] [Related]
10. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
11. Anti-aromatase agents in the treatment and prevention of breast cancer.
Goss P
Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225
[TBL] [Abstract][Full Text] [Related]
12. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Goss PE; Ingle JN; Pritchard KI; Ellis MJ; Sledge GW; Budd GT; Rabaglio M; Ansari RH; Johnson DB; Tozer R; D'Souza DP; Chalchal H; Spadafora S; Stearns V; Perez EA; Liedke PE; Lang I; Elliott C; Gelmon KA; Chapman JA; Shepherd LE
J Clin Oncol; 2013 Apr; 31(11):1398-404. PubMed ID: 23358971
[TBL] [Abstract][Full Text] [Related]
13. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Mouridsen H; Gershanovich M
Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
[TBL] [Abstract][Full Text] [Related]
14. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
Allred DC; Baum M; Buzdar AU; Carlson RW; Dowsett M; Elledge RM; Gradishar WJ; Grana G; Howell A; Mamounas EP
Breast J; 2003; 9(3):213-22. PubMed ID: 12752630
[TBL] [Abstract][Full Text] [Related]
15. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Dodwell D; Vergote I
Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
[TBL] [Abstract][Full Text] [Related]
16. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
17. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
18. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
19. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Carlini P; Frassoldati A; De Marco S; Casali A; Ruggeri EM; Nardi M; Papaldo P; Fabi A; Paoloni F; Cognetti F
Ann Oncol; 2001 Nov; 12(11):1539-43. PubMed ID: 11822752
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Ikeda M; Kurebayashi J; Sonoo H; Miyake A; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K
Gan To Kagaku Ryoho; 2008 Feb; 35(2):261-5. PubMed ID: 18281762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
